Prostate cancer is one of the most frequent cancers globally. 1 out of 8 men will develop prostate cancer once in their lifetime. High incidence of the disease makes a reliable early diagnostic vital for better treatment outcomes. Current prostate cancer detection pathway is still very inaccurate and leads in over half of the cases to unnecessary prostate biopsies, where no cancer is found.

Cambridge Oncometrix has developed a revolutionary non-invasive pre-biopsy diagnostic test that allows for much-improved prostate cancer risk assessment in primary and secondary care.